Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26502029 | 0.89 | CA1 (0.35) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL22022221 | 0.86 | KDM4C (0.50) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL26504296 | 0.84 | CA1 (0.34) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL22166537 | 0.84 | TDP1 (0.32) | — | |
| SCHEMBL24458184 | 0.82 | CA1 (0.44) | CA1KDM4CKDM4APHF8KDM2A | |
| SCHEMBL22021683 | 0.82 | NAMPT (0.32) | — | |
| SCHEMBL24621812 | 0.80 | KDM4C (0.43) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL22166534 | 0.80 | KDM4C (0.43) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL22166501 | 0.80 | KDM4C (0.43) | KDM4CKDM4APHF8KDM2ACHRNB2 | |
| SCHEMBL24458133 | 0.79 | CA1 (0.41) | CA1KDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | CA1 3998/4885KDM4C 2820/4885KDM4A 1981/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CA1 3283/4885KDM4C 2564/4885KDM4A 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.